Sugi Predict

Sugi Predict / Compounds / SCHEMBL2005338

SCHEMBL2005338

SCHEMBL2005338

OB(O)c1cc(F)c(OCc2ccccc2)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LIPE Q05469 1/20 0.47
▸ KDM1A O60341 5/20 0.46
▸ MAOA P21397 2/20 0.46
▸ MAOB P27338 2/20 0.46
▸ THRA P10827 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ FFAR4 Q5NUL3 1/20 0.43
▸ LMNA P02545 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ SLC6A2 P23975 2/20 0.41
▸ SLC6A3 Q01959 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ PTGS1 P23219 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ PTGS2 P35354 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ HTR1A P08908 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1331584 0.86 MAOB (0.46) LIPEKDM1AMAOAMAOBFFAR4
SCHEMBL12138000 0.86 LIPE (0.39) LIPEKDM1AMAOAMAOBTHRA
SCHEMBL9823890 0.82 KDM1A (0.50) KDM1AMAOAMAOBTHRATHRB
SCHEMBL4052775 0.82 BRD4 (0.41) LIPEKDM1AMAOBFFAR4LMNA
SCHEMBL29950742 0.81 LIPE (0.57) LIPETHRATHRBLMNAHPGD
SCHEMBL212034 0.81 LIPE (0.53) LIPEKDM1ANPC1MRGPRX4
SCHEMBL29954345 0.81 LIPE (0.53) LIPEKDM1ANPC1MRGPRX4
SCHEMBL4770265 0.81 THRA (0.44) LIPEKDM1AMAOAMAOBTHRA
SCHEMBL257590 0.80 LIPE (0.56) LIPEFFAR4LMNAHPGDSLC6A2
SCHEMBL2557235 0.80 LIPE (0.47) LIPETHRATHRBLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224599-A1 PYRROLIDINE-BASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2025-10-30 — — WO disclosed
US-20250326741-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2025-10-23 — — US disclosed
US-20230089867-A1 CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER NOVARTIS AG (CH) 2023-03-23 — — US disclosed
CN-113861188-B Pyrazolo [3,4-b ] pyridine derivative, preparation method thereof and application thereof as HPK1 inhibitor 杭州医学院 2023-02-28 — — CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
US-20220315578-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-10-06 — — US disclosed
EP-4041724-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE Novartis AG (CH) 2022-08-17 — — EP disclosed
CN-114641473-A BRD9 bifunctional degradation agent and use method thereof 诺华股份有限公司 2022-06-17 — — CN disclosed
CN-113861188-A Pyrazolo [3,4-b ] pyridine derivative, preparation method thereof and application thereof as HPK1 inhibitor 杭州医学院 2021-12-31 — — CN disclosed
WO-2021055295-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-03-25 — — WO disclosed
WO-2021055295-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-03-25 — — WO disclosed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 — — US disclosed
US-7807068-B2 reacting 4-halo-2,6-difluorophenol with protecting group, dehalogenating to form protected phenol ether group, reacting with boronic acid/ester, coupling in presence of catalyst, deblocking, etherifying, esterifying; for optical, electro-optical and electronic use, liquid-crystal media and displays MERCK PATENT GESELLSCHAFT (DE) 2010-10-05 — — US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 — — US disclosed
EP-2118068-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS Glaxo Group Limited (GB) 2009-11-18 — — EP disclosed
US-20090141215-A1 POLYMERIZABLE COMPOUNDS MERCK PATENT GESELLSCHAFT (DE) 2009-06-04 — — US disclosed
WO-2008107455-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315578-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE BRD9, BRD2, BRD1 LIPE 1600/4885KDM1A 766/4885MAOA 456/4885
US-20090141215-A1 POLYMERIZABLE COMPOUNDS VCL, LCP1, LPXN LIPE 2943/4885KDM1A 4238/4885MAOA 2496/4885
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GPER1, ESR2, ESRRB LIPE 1036/4885KDM1A 2437/4885MAOA 1509/4885
US-20230089867-A1 CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER PCSK9, PCSK7, PCSK6 LIPE 91/4885KDM1A 3162/4885MAOA 2275/4885
US-20250326741-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF GIPR, GLP1R, GPR119 LIPE 103/4885KDM1A 4364/4885MAOA 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.